))
In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals. The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVi ...
…
continue reading
1
Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality
4:20
Oncology Times Broadcast NewsSwedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular MortalityMieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with en…
…
continue reading
1
Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!
6:57
Oncology Times Broadcast NewsAromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–an…
…
continue reading
John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.John Burn, Newcastle University, England
…
continue reading
Oncology Times Broadcast NewsFor Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends SurvivalCharles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen…
…
continue reading
Oncology Times Broadcast News: Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer For adjuvant treatment of stage II and stage III colorectal cancer the vascular endothelial growth factor (VEGF) receptor inhibitor, bevacizumab, gave no benefit in disease-free survival after a median follow up of three years…
…
continue reading
BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-la…
…
continue reading
1
Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos
6:23
Oncology Times Broadcast News: Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab CombosAdding the oral drug capecitabine to a regimen of bevacizumab plus irinotecan was as effective as adding infusions of 5FU/folinic acid for patients who had metastatic colorectal cancer in a phase II study presented to the Wor…
…
continue reading
1
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival
4:37
Oncology Times Broadcast News: Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free SurvivalTreatment of advanced pancreatic islet cell tumors with sunitinib has doubled progression-free survival in patients whose options have been very limited up to now, according to French researchers reporting their phase III r…
…
continue reading
1
Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
3:39
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor status to the choice of molecular therapy for patients with metastatic colorectal cancer. Whether the gene is wild-type or mutant …
…
continue reading
1
Chronic Myeloid Leukemia 'To Become A Very Indolent Disease': Pregnancy Possible, Transplants Avoided—Mission Accomplished?
9:09
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Hagop Kantarjian MD from the MD Anderson Cancer Center in Houston about his latest findings on treating CML in patients who have the T315I mutation. He also discusses the feasibility of patients becoming pregnant while having tyrosine kinase inhibi…
…
continue reading
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Stanley H Winokur MD from Palm Beach, Florida, about his daily internet quiz that gives oncologists the chance to test their knowledge of cancer management by completing an on-line questionnaire taking only a minute. Dr Winokur discusses the role o…
…
continue reading
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Kathy Albain, Professor of Medicine at Loyola University, Chicago, on her return from the 2009 St Gallen consensus meeting which formulated updated recommendations about adjuvant therapy for breast cancer. The 21 gene recurrence score and the 70-ge…
…
continue reading
1
Oropharyngeal Carcinoma: Better Outlook From Human Papilloma Virus-Directed Therapies— Different Patient Characteristics, New Therapeutic Opportunities
6:40
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Marshall Posner MD from the Dana-Farber Cancer Institute in Boston about the increased prevalence of oropharygeal cancers which are related to HPV infection. These tumors may be less aggressive than cancers testing negative for HPV, and have proved…
…
continue reading
Oncology Times Broadcast News with the Audio Journal of OncologyReporting from: 10th European Congress Perspectives in Lung Cancer, Brussels March 6-7, 2009 and Journal of Clinical OncologyCancer Related Fatigue Questionnaires AssessedPaddy Stone of St George's Hospital, University of London and David Cella from Northwestern University Feinberg Sch…
…
continue reading
Oncology Times Broadcast News with the Audio Journal of OncologyReporting from: 10th European Congress Perspectives in Lung Cancer, Brussels March 6-7, 2009 and Journal of Clinical OncologyBilateral Prophylactic Mastetomy For DCISTodd Tuttle from the University of Minnesota in Minneapolis and Abram Recht from Harvard Medical School and the Beth Isr…
…
continue reading
Oncology Times Broadcast News with the Audio Journal of OncologyReporting from: 10th European Congress Perspectives in Lung Cancer, Brussels March 6-7, 2009 and Journal of Clinical OncologyInsulin-Like Growth Factor Inhibition In Lung CancerSilvia Novello, and Giorgio Scagliotti from the University of Turin about harnessing insulin-like growth fact…
…
continue reading
ONCOLOGY TIMES BROADCAST NEWS WITH THE AUDIO JOURNAL OF ONCOLOGY February 2009Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008 IN THIS EDITION:Greater Role for Umbilical Cord Blood in Adult TransplantsMary Eapen, Medical College of Wisconsin, MilwaukeeCOMMENT: Arma…
…
continue reading
Oncology Times Broadcast NewsJanuary 9th, 2009American Society of Hematology 2008 Meeting ReportReporting From the 2008 Annual Meeting of the American Society of Hematology, San FranciscoThe exciting recent ASH conference reflected the vibrant mood of an America boldly tackling economic and political turmoil with post-presidential-election optimism…
…
continue reading
Oncology Times Broadcast News with the Audio Journal of OncologyScientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, MilanPat Price, Christie Hospital, Manchester Gianni Bonadonna, Istituto Nazionale Tumori, Milan REPORTING FROM: National Cancer Research Institute Cancer Conference,…
…
continue reading
